Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study so...

Full description

Saved in:
Bibliographic Details
Main Authors: Qi Cai, Shuhui You, Jinglong Huang, Caifeng Gong, Wen Zhang, Aiping Zhou
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
HER2
non-small cell lung cancer
trastuzumab deruxtecan
second-line treatment
cost-effectiveness
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2468070
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/21645515.2025.2468070

Similar Items